Status:
RECRUITING
Neoadjuvant Radiotherapy and Immediate Implant-Based Breast Reconstruction
Lead Sponsor:
Hubei Cancer Hospital
Conditions:
Breast Cancer
Implant Breast Reconstruction
Eligibility:
FEMALE
18-75 years
Phase:
NA
Brief Summary
Neoadjuvant radiotherapy(NART) followed by mastectomy and immediate DIEP flap reconstruction is feasible and technically safe. However, reports of NACT followed immediate implant-based breast reconstr...
Detailed Description
Radiotherapy after implant-based breast reconstruction have negative effects on implant and cosmetic results, including severe capsular contracture, mastectomy flap necrosis ,reoperation and so on. Po...
Eligibility Criteria
Inclusion
- Women \>18 years with histopathologically-confirmed breast cancer, who:
- require mastectomy for any reason
- a known indication for (adjuvant) radiotherapy
- require implant-based breast reconstruction
Exclusion
- Inability to give informed consent
- MDT unable to make recommendation for radiotherapy based on pre-operative histopathological and imaging findings
- Previous history of breast cancer or another malignancy for which radiotherapy of the breast or axilla
- Pregnant or lactating
- inflammatory breast cancer
Key Trial Info
Start Date :
July 8 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 31 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05992870
Start Date
July 8 2023
End Date
October 31 2025
Last Update
March 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xinhong Wu
Wuhan, Hubei, China, 430079